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Summary 
 
 A total of 2,553 pigs (PIC L337 × C22) 
were used in two experiments in a commercial 
research barn to evaluate the effects of a 
commercially available Porcine Circovirus 
Type 2 (PCV2) vaccine on finisher pig growth 
rate, feed efficiency, and mortality rate.  Pigs 
in Exp. 1 were vaccinated at 9 and 11 wk of 
age while pigs in Exp. 2 were vaccinated ear-
lier at 5 and 7 wk of age. In Exp. 1, 1,300 pigs 
were individually weighed and the vaccine 
treatment administered 15 and 1 d before be-
ing placed on test in the finisher. In Exp. 2 
1,253 pigs were used and randomly allotted 
based on nursery pen average pig weight and 
the vaccine treatment administered 41 and 27 
d before being placed on test in the finisher. 
Pen weights were obtained on d 0 and every 2 
weeks until the end of the trial. Feed intake 
was recorded on a pen basis. In Exp 1, growth 
rate, feed intake, feed efficiency, and mortality 
were improved (P<0.05) in vaccinated pigs 
compared to unvaccinated pigs. In Exp. 2, 
there was a vaccine by sex interaction 
(P<0.01) for ADG 2. The interaction was the 
result of the vaccine increasing ADG to a 
greater extent in barrows than in gilts. The in-
teraction for ADG resulted in a vaccine by sex 
interaction for market weight (P<0.05). Vac-
cinated barrows were 10.6 lb heavier com-
pared to unvaccinated control barrows while 
vaccinated gilts were only 2.1 lb heavier than 
unvaccinated gilts at market.  In Exp. 2, ADFI 
and F/G were numerically better and mortality 
rate was decreased for vaccinated pigs com-
pared to control pigs. In both experiments, 
mortality rates were lower (P<0.05) in vacci-
nated pigs. Vaccinated pigs had 2.6 and 5.9% 
less mortality than non-vaccinated pigs in 
Exp. 1 and 2, respectively. The commercial 
PCV2 vaccine used in this study was effective 
at reducing mortality and increasing growth 
rate in finisher pigs with histopathologic le-
sions suggestive of Porcine Circoviral Disease 
(PCVD).  
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Introduction 
 
Porcine Circovirus Disease (PCVD) is an 
emerging disease in the US and KS that prin-
cipally affects finishing pigs. The disease was 
first described in Canada 10 years ago. Por-
cine Circovirus 2 (PCV2), the causative agent, 
is very difficult to control and is present in 
almost every pig production facility. Clinical 
disease leads to high death loss, and increased 
cull rates in growing and finishing pigs but 
was not thought to greatly affect growth per-
formance in pigs with subclinical infection. 
 
         
 
1Appreciation is expressed to New Horizon Farms for use of pigs and facilities and Richard Brobjorg,
Cal Hulstein, and Marty Heintz for technical assistance. 
2Food Animal Health and Management Center, College of Veterinary Medicine. 
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Fortunately, three commercial PCV2 vaccines 
have become available in the US in the last 
year. A two-dose PCV2 vaccine was intro-
duced by Intervet in 2006 but in very limited 
supply. Thus, very limited data exist that 
document its efficacy under field conditions to 
quantify its impact on finishing pig perform-
ance. Therefore, this trial was conducted to 
evaluate the effects of a 2-dose PCV2 vaccine 
on growth performance, feed efficiency, and 
mortality in a commercial finishing facility.  
 
Procedures 
 
General.  All experimental procedures 
used in these studies were approved by the 
Kansas State University Institutional Animal 
Care and Use Committee. 
 
A total of 1,300 (initially 53.5 lb) and 
1,253 (initially 12.1 lb) pigs were used in Exp. 
1 and 2, respectively. Only pigs that were free 
of any defect and in good body condition were 
included at the time of allotment in both ex-
periments. In Exp. 1, pigs were individually 
weighed, ear tagged for identification, and 
randomly allotted to one of two treatments 
with gilts and barrows equally allocated to 
each treatment group. Thus, average weight 
was identical between vaccinated pigs and 
control pigs prior to vaccination. Two doses of 
vaccine (2 ml per dose, Intervet®) were then 
administered at 9 and 11 weeks of age (15 and 
1 day before being placed on-test).  In Exp 2, 
pens in the nursery were weighed and pens 
were randomly allotted to one of two treat-
ments to have the same starting weight for 
both treatments. The vaccinated pigs were 
given two doses (2 ml per dose) of a commer-
cially available vaccine (Intervet®) adminis-
tered at 5 and 7 weeks of age (d 41 and 27 
prior to being placed on-test). Gilts and bar-
rows were equally allocated in separate pens. 
The on-test period consisted of the last 96 
days in Exp 1 and 105 days in Exp 2 of the 
finishing period. Pigs were weighed every two 
weeks of the finishing phase to determine 
ADG, ADFI, and F/G.  
Both experiments were conducted in a 
commercial research finishing barn in south-
western Minnesota and used similar genetics 
(PIC L337 × C22). Pens were 18 × 10 feet. 
The barns were double curtain sided, with 
completely slatted flooring and a deep pit for 
manure storage. Each pen contained one self-
feeder and one cup waterer. All pigs in both 
treatments in each of the two experiments 
were fed similar diets based on corn-soybean 
meal in a phase feeding scheme. Ractopamine 
HCl (Paylean) was added to the diet from d 84 
to 98 in Exp. 2. Feed was provided with a ro-
botic feeding system to provide feed intake on 
an individual pen basis. During the on-test fin-
isher phase, pen weights and inventories were 
obtained every two weeks. Seven days prior to 
the end of the test period the same number of 
pigs (3 in Exp. 1 and 2 in Exp. 2) were 
weighed and sold, similar to normal proce-
dures in commercial production.  
 
On-test pigs that died during the finishing 
phase were recorded and mortality rate was 
calculated as the number of deaths divided by 
the initial number of pigs placed on test in 
each pen. Samples of clinically affected pigs 
indicative of PCVD were necropsied and tis-
sue samples were submitted to a diagnostic 
laboratory to document PCVD associated le-
sions and PCV2 infection. 
 
Data were analyzed as a 2 × 2 factorial in 
a randomized complete block design.  Analy-
sis of variance was conducted on all data by 
using the GLIMIX procedure of SAS and pen 
was used as the experimental unit.  The fixed 
effects were vaccine treatment (non-
vaccinated control or vaccinated) and sex 
(barrow or gilt). 
 
Results and Discussion 
 
 Experiment 1. Clinical signs and histo-
pathologic lesions consistent with PCVD were 
noted in pigs necropsied from the experiment.  
There were no sex by treatment interaction for 
any response criteria, but as expected, barrows 
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were heavier (P<0.05) than the gilts at the end 
of the trial (Table 1). The barrows also exhib-
ited greater (P<0.05) ADG and feed intake but 
poorer (P<0.05) feed efficiency than gilts. 
in ADG in barrows than in gilts (Table 2). The 
interaction for ADG resulted in a vaccine by 
sex interaction for average weight on d 98 and 
market weight (P<0.05). Vaccinated barrows 
were 11.1 lb heavier than unvaccinated control 
barrows while vaccinated gilts were only 2.6 
lb heavier than unvaccinated gilts at market.  
No significant interactions were observed for 
ADFI, F/G, or mortality. However, magnitude 
of mortality in barrows was greater than in 
gilts (Table 3). 
 
Pigs were put on test in the finisher just af-
ter administration of the second dose of vac-
cine. Vaccinated pigs were 3.21 lb heavier 
than the control pigs at d 89 even though they 
were 1.9 lighter when placed on test.  It should 
be noted that the timing of vaccination was at 
an older age than recommended. At market, 
vaccinated pigs were 2.9 lb heavier per pig 
than the pigs that were not vaccinated. The 
heaviest pigs in each pen (3 pigs per pen) were 
sold 7 days earlier than the rest of the pigs, 
which were weighed at the end of the trial.  
This explains the smaller difference in weights 
at the end of the trial compared to d 89. The 
differences in final weight were due to the 
faster growth rate (P<0.05) of the vaccinated 
pigs during the test period. The vaccinated 
pigs also had increased (P<0.05) feed intake 
and feed efficiency compared to the non-
vaccinated pigs. For a similar weight gain, the 
vaccinated pigs would require 9.4 lb less feed 
than the non-vaccinated pigs. 
 
There were no significant differences in 
feed intake and feed efficiency between vac-
cinated and non-vaccinated groups. Barrows, 
as expected, had greater feed intake but poorer 
feed efficiency compared to gilts (P<0.01), 
and tended to have higher mortality (P = 0.08) 
compared to gilts. 
 
The effect of the vaccine on ADG through 
time indicates that growth rate differences be-
tween control and vaccinated pigs peaked be-
tween the second and sixth week on-test (Fig-
ure 1). Paylean was introduced in the diet dur-
ing the d 84 to 98 period. The decrease in 
ADG in unvaccinated pigs preceded the ob-
served rise in mortality. The greatest differ-
ence in cumulative mortality between vacci-
nated and unvaccinated pigs was noted be-
tween the sixth and twelfth week on-test (Fig-
ure 2). 
 
Mortality rate was significantly reduced 
(P<0.05) in the vaccinated group compared to 
the non-vaccinated group. There was no dif-
ference in mortality rates between gilts and 
barrows although barrow mortality was nu-
merically greater. 
 
In conclusion, the PCV2 vaccine used in 
the experiments was effective in decreasing 
mortality rate and improving the growth per-
formance of pigs in a PCV2-infected herd as 
indicated by heavier weights of the vaccinated 
group. Vaccinated pigs had greater ADG in 
both experiments, significantly improved feed 
efficiency in Exp 1 and numerically improved 
efficiency in Exp 2.   
 
Experiment 2. Clinical signs and histopa-
thologic lesions consistent with PCVD were 
noted in pigs necropsied from the experiment. 
 
There was a vaccine by sex interaction 
(P<0.01) for ADG. The interaction was the 
result of the vaccine causing a greater increase  
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Table 1.  Effects of a PCV2 Vaccinea on Growth Performance and Mortality Rate (Exp 1)b
Vaccine 
Main Effect     
Sex 
Main Effect     P-values 
Item Control Vaccine SE  Barrow Gilt SE  Vaccine Sex 
Vaccine ×
Sex 
Weight, lb           
     D 0 79.0 77.1 0.6 77.9 78.1 0.6 0.02 0.76 0.52 
     D 89c 257.8 261.0 1.2 262.4 256.5 1.2 0.06 0.001 0.69 
     Marketd 259.9 262.8 1.1 264.2 258.5 1.1 0.07 0.0004 0.84 
          
D 0 to 96          
     ADG, lb 2.03 2.10 0.01 2.10 2.03 0.01 <.0001 <.0001 1.00 
     ADFI, lb 5.21 5.30 0.03 5.44 5.06 0.03 0.03 <.0001 0.90 
     F/G 2.57 2.52 0.01 2.59 2.50 0.01 0.01 <.0001 0.85 
          
Mortality, % 5.6 3.0 0.90 4.4 3.8 0.80 0.02 0.62 0.35 
aCommercial PCV2 vaccine (Intervet; 2 ml per dose) administered at 9 and 11 weeks of age to the 
vaccine treatment (15 and 1 d prior to being placed on-test in the finisher) .   
bTotal of 1,300 pigs were individually weighed and randomly assigned to one of the two treatments 
within barrows and gilts prior to administration of the first vaccine dose. Thus, average weight (53.5 
lb) was identical between vaccinated pigs and control pigs prior to vaccination. 
cDay 89 was the last day that all pigs remained in the pen prior to topping the heaviest 3 pigs in each 
pen. 
dMarket weight was the average weight of the three pigs topped 7 days before the end of the trial (d 
89) and the pigs remaining at the end of the trial (d 96). 
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Table 2.  Effects of Gender on the Efficacy of a PCV2 Vaccineab (Exp. 2) 
Control  Vaccine  P-values 
Item Barrow Gilt Barrow Gilt  SE  Vaccine×sex 
Weight, lb               
     D 0 57.5 57.8 56.4 56.6 0.7 0.96 
     D 98 250.6d 248.2d 260.4e 250.0d 2.0 0.05 
     Marketc 264.4d 261.8d 275.0e 263.9d 1.0 0.04 
       
D 0 to 105       
     ADG, lb 1.97d 1.94d 2.08e 1.97d 0.01 0.01 
     ADFI, lb 5.10 4.82 5.25 4.82 0.07 0.27 
     F/G 2.59 2.48 2.52 2.45 0.03 0.68 
       
Mortality, % 12.1 6.5 3.3 2.6  0.15 0.45 
aCommercial PCV2 vaccine (Intervet; 2 ml per dose) administered at 5 and 7 weeks of age to the 
vaccine treatement (41 and 27 d prior to being placed on-test in the finisher).  
bA total of 1,253 pigs (initially 12.1 lb) were randomly assigned by nursery pen average weight to 
one of the two treatments within barrows and gilts prior to administration of the first vaccine dose. 
cMarket weight was the average weight of pigs topped 7 days before the end (d 98) of the trial and 
the pigs remaining at the end of the trial (d 105).   
d,eMeans in the same row with different superscripts differ (P<0.05). 
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Table 3.  Main Effects of a PCV2 Vaccinea on Growth Performance and Mortality Rateb
(Exp. 2) 
Vaccine main effect   Sex main effect   P-values 
Item Control Vaccine SE  Barrow Gilt SE  Vaccine Sex 
Weight, lb                 
     D 0 57.6 56.5 0.7 57.0 57.2 0.7 0.28 0.84 
     D 98 249.4 255.2 1.4 255.5 249.2 1.4 0.005 0.003 
     Marketc 263.1 269.4 1.4 269.7 262.8 1.4 0.004 0.002 
         
D 0 to 105         
     ADG, lb 1.96 2.03 0.01 2.03 1.96 0.01 <.0001 0.0001
     ADFI, lb 4.96 5.04 0.05 5.18 4.82 0.05 0.28 <.0001
     F/G 2.54 2.48 0.025 2.56 2.46 0.025 0.14 0.01 
         
Mortality, % 8.9 3.0  0.1 6.5 4.1 0.1  <.0001 0.08 
aCommercial PCV2 vaccine (Intervet; 2 ml per dose) administered at 5 and 7 weeks of age to the 
vaccine treatment (41 and 27 d prior to being placed on-test in the finisher).  
bA total of 1,253 pigs (initially 12.1 lb) were randomly assigned by nursery pen average weight to 
one of the two treatments within barrows and gilts prior to administration of the first vaccine dose.  
cMarket weight was the average weight of pigs topped 7 days before the end (d 98) of the trial and 
the pigs remaining at the end of the trial (d 105). 
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Figure 1. Growth Rate During Each Period for Unvaccinated Pigs (█) Compared to PCV2 
Vaccinated Pigs  (█) Over Time (Exp. 2; d 0 to 105). 
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Figure 2. Effect of PCV2 Vaccination on Cumulative Mortality Rate in Non-vaccinated 
Pigs (█) and Vaccinated Pigs (█) from D 0 to 105 on-Test (Exp. 2). 
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